BOJIMED
Boji Medical Technology Co., Ltd. was founded in 2002 and listed on the Shenzhen Stock Exchange in 2015. As a leading Contract Research Organization (CRO), it specializes in providing innovative drug R&D and manufacturing services with a one-stop, full-process solution for pharmaceutical companies worldwide.
-
1500+
Number of employees
-
2000+
Number of customers
-
4000+
Number of projects
-
900+
Partner Organizations
Business Introduction
01
Clinical Research Services
01
Clinical Research Services
Comprehensive support spanning clinical trial protocol design, project management, data statistics, and analysis, enabling the safe and effective clinical validation of drugs...
02
Preclinical Research Services
02
Preclinical Research Services
Conduct pharmacodynamic, pharmacokinetic, and toxicological studies to establish a foundation for candidate drug screening and optimization, thereby reducing R&D risks...
03
Full-chain Services for Traditional Chinese Medicine R&D
03
Full-chain Services for Traditional Chinese Medicine R&D
From herbal extraction and process development to quality standard formulation and clinical trial applications, covering every stage of traditional Chinese medicine research and development...
04
Overseas R&D Operations
04
Overseas R&D Operations
Aligning with international regulatory requirements, we provide overseas clinical trial planning, application submission, and project execution services to advance the global expansion of pharmaceutical products...
05
Therapeutic Areas
05
Therapeutic Areas
Focusing on multiple disease areas including oncology, anti-infectives (hepatology), cardiovascular, neurology, and endocrinology, we provide specialized R&D solutions...
06
Ongoing Project Transfer
06
Ongoing Project Transfer
Integrate high-quality pipeline resources, provide project transfer and collaboration opportunities, and accelerate the commercialization of R&D outcomes...
BOJI VIEW
2026-08-04
Omalizumab for Injection (Shuyang Shule®) Approved for Market Launch! BojiMed Supports Its Phase III Clinical Research
2026-09-03
BojiMed and Huawei Sign Cooperation Agreement to Jointly Build a New AI+CRO Intelligent R&D Paradigm
2026-08-05
Boji's Expert Stewardship | Astem-101 Stem Cell Therapy Investigator Seminar Concludes with Resounding Success
-
Omalizumab for Injection (Shuyang Shule®) Approved for Market Launch! BojiMed Supports Its Phase III Clinical Research2026.08.04
-
BojiMed and Huawei Sign Cooperation Agreement to Jointly Build a New AI+CRO Intelligent R&D Paradigm2026.09.03
-
Boji's Expert Stewardship | Astem-101 Stem Cell Therapy Investigator Seminar Concludes with Resounding Success2026.08.05